GlassScriptPhysician profile
Martin Z Jimenez
NPI 1043225923
$5,468.90
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $881 · 2021: $1,229 · 2022: $1,107 · 2023: $859 · 2024: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,150.08 | 2019-2024 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $641.09 | 2019-2024 | Xifaxan |
| Amgen INC. | $549.42 | 2019-2024 | Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $364.20 | 2019-2024 | Hetlioz, Fanapt |
| Grifols USA, LLC | $333.68 | 2019-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $286.16 | 2021-2024 | |
| Mylan Specialty L.P. | $269.71 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $198.89 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $196.09 | 2019-2023 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $190.02 | 2020-2022 | |
| Daiichi Sankyo INC. | $185.68 | 2019-2022 | |
| Radius Health, INC. | $166.06 | 2019-2023 | |
| Philips North America LLC | $148.82 | 2019-2024 | (Ak6) Vest Therapy |
| Kowa Pharmaceuticals America, INC. | $146.25 | 2019-2024 | Livalo |
| Pfizer INC. | $118.02 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $109.10 | 2019-2021 | |
| Amarin Pharma, INC. | $102.77 | 2020-2022 | |
| Esperion Therapeutics, INC. | $42.22 | 2021 | |
| Paratek Pharmaceuticals, INC. | $32.17 | 2022-2024 | Nuzyra |
| Arbor Pharmaceuticals, INC. | $28.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.50 | 2020-2021 | |
| Boston Scientific Corporation | $24.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.29 | 2019 | |
| Abbvie INC. | $20.78 | 2021 | |
| Tactile Systems Technology INC | $16.53 | 2020 | |
| Medicure Pharma INC. | $13.56 | 2021 | |
| Medtronic, INC. | $13.37 | 2022 | |
| Merck Sharp & Dohme LLC | $13.28 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.15 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 | |
| Allergan, INC. | $11.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.35 | 2021 | |
| Seqirus USA INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.